From: Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Gene name | Mutated position | neopeptide | HLA restriction | References |
---|---|---|---|---|
Gene fusion | ||||
CBFB-MYH11 | / | REEMEVHEL | B*40:01 | [53] |
PML-RARA | / | NSNHVASGAGEAAIETQSSSSEEIV | DR*11 | [56] |
DEK-CAN | / | TMKQICKKEIRRLHQY | DR*53; DR*9 | [101] |
Indels | ||||
NPM1 | 283–291 | AIQDLCLAV | A*02:01 | |
283–291 | AIQDLCVAV | A*02:01 | ||
289–297 | LAVEEVSLR | A*02:01 | [61] | |
290–298 | AVEEVSLRK | A*02:01 | [61] | |
288–296 | CLAVEEVSL | A*02:01 | [62] | |
FLT3-ITD | / | YVDFREYEYY | A*01:01 | [68] |
Non-synonymous point mutations | ||||
IDH1 | R132H | GWVKPIIIGHHAYGDQYRAT | DRB1*0101 | [74] |
KRAS | G12D | GADGVGKSA | C*08:02 | [83] |
G12D | GADGVGKSAL | C*08:02 | [83] | |
G12D | VVVGADGVGK | A*11:01 | [102] | |
G12V | VVVGAVGVGK | A*11:01 | [102] | |
TP53 | R175H | HMTEVVRHC | A*02:01 | |
R175H | YKQSQHMTEVVRHCPHHERCSDSDG | Class II | [89] | |
R175H | VVRHCPHHERCSDSD | DRB1*13:01 | [89] | |
R175H | QHMTEVVRHCPHHER | DRB1*13:01 | [89] | |
Y220C | RNTFRHSVVVPCE | DRB1*04:01 | [89] | |
Y220C | VVPCEPPEV | A*02:01 | [89] | |
Y220C | NTFRHSVVVPCEPPE | DRB3*02:02 | [89] | |
G245S | HYNYMCNSSCMGSMN | DRB3*02:02 | [89] | |
R248Q | YMCNSSCMGGMNQRPILTIITLEDS | Class I and II | [89] | |
R248W | SSCMGGMNWR | A*68:01 | [89] | |
R248W | SCMGGMNWRPILTII | DRB1*02:01 | [89] | |
R248W | FEVRVCACPGRDWRTEEENLRKKGE | Class II | [89] | |
G245S | HYNYMCNSSCMGSMN | DRB3*02:02:01 | [90] | |
Y220C | NTFRHSVVVPCEPPE | DRB3*02:02:01 | [90] | |
P190L | ALPQHLIRV | A*0201 | [91] | |
R267P | LLGPNSFEV | A*0201 | [91] | |
A161T | RVRAMTIYKQ | A*1101 | [93] | |
Splicing variants | ||||
SF3B1 | R625C/H/L/S | LLIRWQHFL | A*0201 | [99] |
AALPILFQV | A*0201 | [99] | ||
ALLLQLFTL | A*0201 | [99] | ||
ALLPGLPAA | A*0201 | [99] | ||
RLPGVLPRA | A*0201 | [99] |